Weight Loss Rankings launches as a free, independent, bilingual directory that scores GLP-1 telehealth providers on price, clinical oversight, and safety. It pairs independent 0-10 provider scores with an evidence-based, PMID-cited research library and free consumer tools.
New York City, United States — July 7, 2026 — Weight Loss Rankings today launched as a free, fully independent consumer resource that brings evidence-based transparency to the fast-growing market for GLP-1 weight-loss medications. As demand for drugs like semaglutide and tirzepatide reshapes weight care, patients face a crowded field of telehealth providers, compounded and brand-name options, and comparison sites that rarely explain how they reach their conclusions. Weight Loss Rankings scores every major GLP-1 telehealth provider on transparent, published criteria.
Every provider receives an independent 0-10 score based on a publicly documented methodology that weighs real-world pricing, physician oversight, shipping reliability, and patient safety. Consumers can explore in-depth provider reviews and compare the top-rated semaglutide providers on price, visit frequency, and clinical credentials.
“Consumers deserve the same evidence standards in weight-loss information that they expect from their doctor,” said Eli Marsden, Founding Editor of Weight Loss Rankings. “Every claim is sourced to primary literature, and every score is explained in plain language, so people can see exactly how we reached it.”
The platform is built to a clinical-publication standard that is rare among comparison sites. Its research library offers a large and continually growing collection of evidence-based articles in both English and Spanish, each citing peer-reviewed studies and official FDA communications, with named authors. That rigor extends to evidence-graded coverage of compounded and brand-name semaglutide and tirzepatide, peptide therapies, and emerging agents such as orforglipron, retatrutide, and cagrisema.
Weight Loss Rankings is fully bilingual in English and Spanish, a rarity in a market where Spanish-speaking patients are among the fastest-growing groups seeking GLP-1 care. Its free tools include a live price tracker, a savings calculator, BMI and dosing references, and an FDA warning-letters tracker.
“The GLP-1 shift has created real opportunity, and real risk of patient harm,” Marsden added. “We want everyone researching these medications to make an informed decision, regardless of budget or first language.”
About Weight Loss Rankings
Weight Loss Rankings is a free, independent consumer platform bringing transparency and evidence-based rigor to the GLP-1 and weight-loss telehealth market. It provides independent provider scores, a large library of clinically cited articles, a full suite of free tools, and coverage of compounded and brand-name semaglutide and tirzepatide as well as emerging therapies, all in English and Spanish. The scoring methodology is publicly documented, and affiliate relationships are disclosed.
###
Media Contact
Company: Weight Loss Rankings
Contact Person: Eli Marsden
Email: Send email
Website: www.weightlossrankings.org
